Management of Bone Disease and Body Composition Changes

  • Author: Donald P. Kotler, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 5/7/18 (What's New)

Summary

  • Use of the thymidine analogue NRTIs that are associated with lipoatrophy has waned in favor of NRTIs that are more tolerable, such as tenofovir DF, abacavir, and tenofovir AF
  • Many clinicians agree that prevention of lipoatrophy is a better practice than trying to reverse the process once it is clinically evident

Action required